Bruce D. Dorsey

4.3k citations

66 papers · 2.6k indexed · h-index 25

Co-authors: Joseph P. Vacca Rhonda B. Levin Stacey L. McDaniel William A. Schleif Arup K. Ghose John P. Mallamo Robert L. Hudkins Torsten Herbertz
Topics: HIV/AIDS drug development and treatment (14 papers)Lung Cancer Treatments and Mutations (11 papers)Cancer therapeutics and mechanisms (10 papers)
Cited by: Virology Organic Chemistry Infectious Diseases
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Blood
Partner nations: United States Italy Spain

In The Last Decade

Bruce D. Dorsey

66 papers receiving 2.5k citations

Peers

Countries citing papers authored by Bruce D. Dorsey

Since Specialization

Citations

This map shows the geographic impact of Bruce D. Dorsey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce D. Dorsey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce D. Dorsey more than expected).

Fields of papers citing papers by Bruce D. Dorsey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce D. Dorsey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce D. Dorsey. The network helps show where Bruce D. Dorsey may publish in the future.

Co-authorship network of co-authors of Bruce D. Dorsey

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce D. Dorsey. A scholar is included among the top collaborators of Bruce D. Dorsey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce D. Dorsey. Bruce D. Dorsey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators 2024 ·ACS Medicinal Chemistry Letters ·Eugen F. Mesaros,Andrew G. Cole,Steven G. Kultgen,Nagraj Mani,Kristi Fan,(unknown),(unknown),(unknown),Holly M. Micolochick Steuer,(unknown),(unknown),Troy O. Harasym,Angela M. Lam,Emily P. Thi,Bruce D. Dorsey,Michael J. Sofia	2
2	Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836 2024 ·Journal of Medicinal Chemistry ·Andrew G. Cole,Steven G. Kultgen,Nagraj Mani,Kristi Fan,(unknown),(unknown),Bruce D. Dorsey,Eugen F. Mesaros,Emily P. Thi,(unknown),(unknown),Troy O. Harasym,Amy C. H. Lee,Andrea Olland,R.K. Suto,Michael J. Sofia	4
3	Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors 2019 ·Antiviral Research ·(unknown),Nagraj Mani,Bruce D. Dorsey,(unknown),René Rijnbrand,Michael J. Sofia,John E. Tavis	30
4	Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review 2014 ·Expert Opinion on Therapeutic Patents ·Eugen F. Mesaros,Gregory R. Ott,Bruce D. Dorsey	20
5	Synthesis and biological evaluation of sulfonyl acrylonitriles as novel inhibitors to peritoneal carcinomatosis 2012 ·Bioorganic & Medicinal Chemistry Letters ·Craig A. Zificsak,Yi Shen,Joseph G. Lisko,Jay Theroff,(unknown),(unknown),Xiufen Li,Bruce D. Dorsey,Scott K. Kuwada	11
6	CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers 2011 ·Molecular Cancer Therapeutics ·Mangeng Cheng,Matthew R. Quail,Diane E. Gingrich,Gregory R. Ott,Lihui Lü,Weihua Wan,Mark S. Albom,Thelma S. Angeles,Lisa D. Aimone,(unknown),Rodolfo Machiorlatti,(unknown),Mark A. Ator,Bruce D. Dorsey,Giorgio Inghirami,Bruce Ruggeri	59
7	A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis 2011 ·Arthritis Research & Therapy ·(unknown),Lily Lu,Paweł Dobrzański,Cynthia Serdikoff,Diane E. Gingrich,(unknown),Thelma S. Angeles,Mark S. Albom,Mark A. Ator,Bruce D. Dorsey,Bruce Ruggeri,Matthew M. Seavey	65
8	Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Craig A. Zificsak,Jay Theroff,Lisa D. Aimone,Thelma S. Angeles,Mark S. Albom,Mangeng Cheng,Eugen F. Mesaros,Gregory R. Ott,Matthew R. Quail,Ted L. Underiner,Weihua Wan,Bruce D. Dorsey	18
9	2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Mark S. Albom,Thelma S. Angeles,Henry J. Breslin,Diane E. Gingrich,Zeqi Huang,Joseph G. Lisko,Jennifer L. Mason,Karen L. Milkiewicz,(unknown),Ted L. Underiner,Gregory J. Wells,Kevin J. Wells‐Knecht,Bruce D. Dorsey	17
10	P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position 2010 ·Bioorganic & Medicinal Chemistry Letters ·Richard C.A. Isaacs,(unknown),(unknown),Swati P. Mercer,Bruce D. Dorsey,Colleen M. McDonough,Jacquelynn J. Cook,Julie A. Krueger,Sidney D. Lewis,Bobby J. Lucas,Elizabeth A. Lyle,Joseph J. Lynch,Cynthia Miller‐Stein,(unknown),Audrey A. Wallace,Rebecca B. White,Bradley K. Wong	3
11	Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Mark S. Albom,Thelma S. Angeles,Jean Husten,Joseph G. Lisko,Robert J. McHugh,Karen L. Milkiewicz,S. N. Prasanna Murthy,Gregory R. Ott,Jay Theroff,Rabindranath Tripathy,Ted L. Underiner,Craig A. Zificsak,Bruce D. Dorsey	22
12	Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models 2010 ·Bioorganic & Medicinal Chemistry Letters ·Eugen F. Mesaros,Jason P. Burke,Jonathan D. Parrish,(unknown),Andrew V. Anzalone,Thelma S. Angeles,Mark S. Albom,Lisa D. Aimone,Matthew R. Quail,Weihua Wan,Lihui Lü,Zeqi Huang,Mark A. Ator,Bruce Ruggeri,Mangeng Cheng,Gregory R. Ott,Bruce D. Dorsey	27
13	2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines 2010 ·Bioorganic & Medicinal Chemistry Letters ·Craig A. Zificsak,Jay Theroff,Lisa D. Aimone,Mark S. Albom,Thelma S. Angeles,(unknown),(unknown),Jennifer V. Grobelny,Torsten Herbertz,Jean Husten,Laura S. Kocsis,(unknown),Sheila Miknyoczki,S. N. Prasanna Murthy,(unknown),Ted L. Underiner,Kevin J. Wells‐Knecht,(unknown),(unknown),Bruce D. Dorsey	13
14	Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation 2009 ·Bioorganic & Medicinal Chemistry Letters ·Bin Liu,(unknown),Bruce D. Dorsey,(unknown),(unknown),Marina Bukhtiyarova,Eric B. Springman	12
15	Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Philip E.J. Sanderson,Matthew G. Stanton,Bruce D. Dorsey,Terry A. Lyle,Colleen M. McDonough,William M. Sanders,(unknown),Adel M. Naylor-Olsen,Julie A. Krueger,Sidney D. Lewis,Bobby J. Lucas,Joseph J. Lynch,Youwei Yan	21
16	An alternate binding site for the P1–P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease 2000 ·Acta Crystallographica Section D Biological Crystallography ·Sanjeev Munshi,Zhongguo Chen,Youwei Yan,Ying Li,David B. Olsen,(unknown),(unknown),Bruce D. Dorsey,Lawrence C. Kuo	28
17	Metabolite–P450 Complex Formation by Methylenedioxyphenyl HIV Protease Inhibitors in Rat and Human Liver Microsomes 1998 ·Biochemical Pharmacology ·Masato Chiba,Joy A. Nishime,I‐Wu Chen,Kari Vastag,(unknown),Byeong Moon Kim,Bruce D. Dorsey,Joseph P. Vacca,Jiunn H. Lin	8
18	A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site 1995 ·Journal of Medicinal Chemistry ·M. Katharine Holloway,Jenny Wai,Thomas A. Halgren,Paula M.D. Fitzgerald,Joseph P. Vacca,Bruce D. Dorsey,Rhonda B. Levin,Wayne J. Thompson,(unknown)	178
19	A practical synthesis of 5‐(chloromethyl)furo[2,3‐b]pyridine, a key intermediate for the HIV protease inhibitor, L‐754,394 1995 ·Journal of Heterocyclic Chemistry ·M. Bhupathy,David A. Conlon,Kenneth M. Wells,John Nelson,Paul J. Reider,Kai Rossen,Jess W. Sager,R. P. Volante,Bruce D. Dorsey,J. M. HOFFMAN,(unknown),Stacey L. McDaniel	30
20	L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor 1994 ·Journal of Medicinal Chemistry ·Bruce D. Dorsey,Rhonda B. Levin,Stacey L. McDaniel,Joseph P. Vacca,James P. Guare,(unknown),(unknown),Emilio A. Emini,William A. Schleif	324

About Bruce D. Dorsey

Bruce D. Dorsey is a scholar working on Hepatology, Virology and Infectious Diseases, having authored 66 papers that have together received 2.6k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (14 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer therapeutics and mechanisms (10 papers). The work is most often cited by research in Virology (440 citations), Organic Chemistry (921 citations) and Infectious Diseases (571 citations). Bruce D. Dorsey has collaborated with scholars based in United States, Italy and Spain. Frequent co-authors include Joseph P. Vacca, Rhonda B. Levin, Stacey L. McDaniel, William A. Schleif, Arup K. Ghose, John P. Mallamo, Robert L. Hudkins, Torsten Herbertz, Joan A. Zugay and J C Quintero. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact